Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHCR7 | Q9UBM7 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CMA1 | P23946 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 7/20 | 0.41 |
| ▸ | DRD3 | P35462 | 3/20 | 0.41 |
| ▸ | DRD4 | P21917 | 2/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
| ▸ | DRD1 | P21728 | 4/20 | 0.41 |
| ▸ | ACHE | P22303 | 4/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | DRD5 | P21918 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3050133 | 0.87 | DHCR7 (0.55) | DHCR7CA2CA9ALDH1A1CMA1 | |
| SCHEMBL3051401 | 0.85 | CHRNA7 (0.49) | CA2CA9ALDH1A1DRD2SIGMAR1 | |
| SCHEMBL3056180 | 0.82 | CA9 (0.72) | CA2CA9DRD2DRD3DRD1 | |
| SCHEMBL3052036 | 0.76 | DHCR7 (0.80) | DHCR7CA2CA9ALDH1A1DRD2 | |
| SCHEMBL3054594 | 0.75 | CA2 (0.48) | DHCR7CA2CA9DRD2DRD3 | |
| SCHEMBL3054533 | 0.74 | DHCR7 (0.70) | DHCR7CA2CA9ALDH1A1DRD2 | |
| SCHEMBL3055295 | 0.74 | DHCR7 (0.58) | DHCR7CA2CA9ALDH1A1CMA1 | |
| SCHEMBL3057653 | 0.73 | DRD2 (0.61) | DHCR7ALDH1A1DRD2DRD3DRD1 | |
| SCHEMBL5025188 | 0.72 | BCHE (0.50) | CA2CA9SIGMAR1 | |
| SCHEMBL18098775 | 0.72 | CA2 (0.70) | DHCR7CA2CA9ALDH1A1CMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394825-B2 | Compound | STERIX LIMITED (GB) | 2013-03-12 | — | — | US | disclosed |
| US-20100222299-A1 | COMPOUND | STERIX LIMITED (GB) | 2010-09-02 | — | — | US | disclosed |
| EP-2155192-A2 | TETRAHYDROISOQUINOLINES AS TUMOUR GROWTH INHIBITORS | Sterix Limited (GB) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008117061-A2 | TETRAHYDROISOQUINOLINES AS TUMOUR GROWTH INHIBITORS | STERIX LIMITED (GB) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222299-A1 | COMPOUND | MKI67, VHL, MYC | DHCR7 421/4885CA2 1077/4885CA9 1002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.